Chronic kidney disease (CKD) is a progressive condition characterized by a gradual loss of kidney function, affecting over 850 million people globally. It is projected to be the fifth leading cause of years of life lost by 2040. There is a high unmet clinical need for better chronic kidney disease therapeutics, as current treatment options, such as renin-angiotensin system inhibitors, only slow disease progression. The growing focus on novel therapies, including SGLT2 inhibitors, endothelin receptor antagonists, and regenerative medicine, is driving drug pipeline advancements. Emerging chronic kidney disease drug candidates aim to improve outcomes and address complications, supporting significant market growth in the coming years.
The Chronic Kidney Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into chronic kidney disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic kidney disease. The chronic kidney disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic kidney disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic kidney disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic kidney disease.
Chronic kidney disease is a long-term condition where the kidneys gradually lose their function, often due to diabetes, hypertension, or genetic factors. This disease affects more than millions of people and leads to end-stage renal failure if left untreated. Current pipeline drug candidates aim to address the progressive nature of chronic kidney disease, focusing on slowing its progression and improving kidney function.
Chronic kidney disease treatments aim to control underlying causes, such as hypertension and diabetes, with medications like ACE inhibitors and SGLT2 inhibitors. Dialysis or kidney transplants may be necessary for advanced stages. Research is focused on developing novel therapeutics that target fibrosis, inflammation, and renal repair to slow disease progression and enhance patient outcomes.
Chronic kidney disease affects over 850 million people worldwide and is projected to become the fifth leading cause of years of life lost by 2040. In the United States, 14% of adults are impacted, while 13% of Japan's adult population suffers from chronic kidney disease. The prevalence in India has reached epidemic levels, with 4%-20% affected. Approximately 7.2 million people are diagnosed with chronic kidney disease stages 1-5 in the United Kingdom, with 3.25 million in later stages.
This section of the report covers the analysis of chronic kidney disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total chronic kidney disease clinical trials.
The drug molecule categories covered under the chronic kidney disease pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, and cell-based therapies. The chronic kidney disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic kidney disease.
The EMR report for the chronic kidney disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic kidney disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic kidney disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic kidney disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic kidney disease drug candidates.
AstraZeneca is sponsoring a Phase IV study to evaluate the efficacy and safety of dapagliflozin in Chinese adults with chronic kidney disease. This single-arm, open-label trial aims to assess its role in preventing chronic kidney disease progression. The study, which began on September 10, 2024, is expected to be completed by June 21, 2027, with approximately 700 participants.
A Phase 2 study, sponsored by Novo Nordisk A/S, is investigating the efficacy, safety, and pharmacokinetics of NNC0519-0130 in reducing kidney damage in individuals with chronic kidney disease (CKD), with or without type 2 diabetes. With an estimated enrollment of 465 participants, the study is expected to be completed by July 30, 2026.
AstraZeneca is sponsoring a Phase 1b study to assess the safety, tolerability, and pharmacodynamics of AZD4144 in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The randomized, placebo-controlled trial will enroll around 28 participants. The study is expected to conclude by August 21, 2025, and includes a 28-day treatment period along with follow-up assessments.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Kidney Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for chronic kidney disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic kidney disease collaborations, regulatory environments, and potential growth opportunities.
Polycystic Kidney Disease Drug Pipeline
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share